Search Within

Jacklynn V Egger

Formats
  1. Meeting Abstract (35)
  2. Journal Article (32)
  3. Editorial (2)
Groups
  1. Department of Medicine (69)
  2. Solid Tumor Oncology Division (69)
  3. Thoracic Oncology (69)
  4. GSK Faculty (54)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (48)
  6. Department of Pathology and Laboratory Medicine (48)

More Groups

People
  1. Charles Rudin (45)
  2. Hira Rizvi (29)
  3. Matthew Hellmann (28)
  4. Natasha Rekhtman (27)
  5. Triparna Sen (24)
  6. Michael Offin (21)

More People

Years
  1. 2025 (2)
  2. 2024 (3)
  3. 2023 (9)
  4. 2022 (21)
  5. 2021 (20)
  6. 2020 (12)

More Years

Publications
  1. Journal of Clinical Oncology (16)
  2. Journal of Thoracic Oncology (13)
  3. Annals of Oncology (6)
  4. Clinical Cancer Research (6)
  5. Cancer Research (4)
  6. Laboratory Investigation (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (17)
  2. Elsevier Inc. (14)
  3. American Association for Cancer Research (13)
  4. Oxford University Press (8)
  5. Nature Publishing Group (5)
  6. Nature Research (5)

More Publishers

Results (69)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Factors associated with disease progression after discontinuation of immune checkpoint inhibitors for immune-related toxicity in patients with advanced non-small cell lung cancer
    Journal Article

    Pecci, F.; Thummalapalli, R.; Alden, S. L.; Ricciuti, B.; Alessi, J. V.; Elkrief, A.; Rizvi, H.; Wang, X.; Jeng, M.; Egger, J. V.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Chromothripsis-mediated small cell lung carcinoma
    Journal Article

    Rekhtman, N.; Tischfield, S. E.; Febres-Aldana, C. A.; Lee, J. J. K.; Chang, J. C.; Herzberg, B. O.; Selenica, P.; Woo, H. J.; Vanderbilt, C. M.; Yang, S. R.; more...
    Cancer Discovery (2025)

    Fulltext@MSK | Save
  • Intratumoral escherichia is associated with improved survival to single-agent immune checkpoint inhibition in patients with advanced non–small-cell lung cancer
    Journal Article

    Elkrief, A.; Montesion, M.; Sivakumar, S.; Hale, C.; Bowman, A. S.; Begüm Bektaş, A.; Bradic, M.; Kang, W.; Chan, E.; Gogia, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Signatures of early plasticity in the histological transformation of lung cancer
    Meeting Abstract

    Rakhade, S.; Chen, M. F.; Quintanal-Villalonga, A.; Sabet, A.; Manoj, P.; Chaudhary, O.; Xu, T.; Masilionis, I.; Falcon, C. J.; Egger, J. V.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Prognostic implications of small cell lung cancer transcriptional subtyping for CNS metastases
    Journal Article

    Tringale, K. R.; Skakodub, A.; Egger, J.; Eichholz, J.; Yu, Y.; Gomez, D.; Rimner, A.; Li, B.; Yamada, Y.; Wilcox, J.; more...
    JCO Precision Oncology (2024)

    Fulltext@MSK | Save
  • Prognostic implications of small cell lung cancer (SCLC) transcriptional subtyping for central nervous system (CNS) metastases
    Meeting Abstract

    Skakodub, A.; Tringale, K.; Egger, J.; Eichholz, J.; Yu, Y.; Gomez, D.; Rimner, A.; Li, B.; Yamada, Y.; Wilcox, J.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes of combination platinum-doublet chemotherapy and anti-PD(L)-1 blockade in KRAS(G12C) mutant non-small cell lung cancer
    Journal Article

    Elkrief, A.; Riccuiti, B.; Alessi, J. V.; Fei, T.; Kalvin, H. L.; Egger, J. V.; Rizvi, H.; Thummalapalli, R.; Lamberti, G.; Plodkowski, A.; more...
    The Oncologist (2023)

    Fulltext@MSK | Save
  • Factors associated with disease progression after discontinuation of immunotherapy for immune-related toxicity in non-small cell lung cancer
    Meeting Abstract

    Pecci, F.; Thummalapalli, R.; Alden, S.; Ricciuti, B.; Alessi, J. V.; Elkrief, A.; Rizvi, H.; Wang, X.; Egger, J. V.; Vaz, V. R.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Clinical benefit from immunotherapy in patients with SCLC is associated with tumor capacity for antigen presentation
    Journal Article

    Rudin, C. M.; Balli, D.; Lai, W. V.; Richards, A. L.; Nguyen, E.; Egger, J. V.; Choudhury, N. J.; Sen, T.; Chow, A.; Poirier, J. T.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study
    Journal Article

    Elkrief, A.; Alessi, J. M. V.; Ricciuti, B.; Brown, S.; Rizvi, H.; Preeshagul, I. R.; Wang, X.; Pecci, F.; Di Federico, A.; Lamberti, G.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save